Structure Therapeutics (GPCR) Assets (2022 - 2026)
Structure Therapeutics (GPCR) posted quarterly Assets of $1.5 billion for Q1 2026, up 74.04% year-over-year from $866.5 million in Q1 2025, and down 4.79% quarter-over-quarter from $1.6 billion in Q4 2025.
Structure Therapeutics (GPCR) Assets (2022 - 2026) Analysis & Trends
Structure Therapeutics' Assets history runs 5 years deep, the most recent figure standing at $1.5 billion for Q1 2026.
- In Q1 2026, Assets rose 74.04% year-over-year to $1.5 billion; the TTM figure through Mar 2026 stood at $1.5 billion (up 74.04% YoY), while the FY2025 annual figure was $1.6 billion, up 75.34% from the prior year.
- Assets for Q1 2026 stood at $1.5 billion, down from $1.6 billion in the prior quarter.
- The five-year high for Assets was $1.6 billion in Q4 2025, with the low at $97.8 million in Q4 2022.
- The 5-year median for Assets is $824.3 million (2025), against an average of $722.9 million.
- The sharpest annual moves came in 2023 and 2025: Assets surged 392.63% in 2023, then fell 13.79% in 2025.
- Structure Therapeutics' Assets stood at $97.8 million in 2022, then soared by 392.63% to $482.0 million in 2023, then soared by 87.41% to $903.3 million in 2024, then surged by 75.34% to $1.6 billion in 2025, then slipped by 4.79% to $1.5 billion in 2026.
- Business Quant data shows GPCR's Assets at $1.5 billion in Q1 2026, $1.6 billion in Q4 2025, and $832.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Structure Therapeutics | 11.65 Bn | 11.65 Bn | - | 1.43 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.43 Bn |
| Mar 31, 2026 | 1.51 Bn |
| Dec 31, 2025 | 1.58 Bn |
| Sep 30, 2025 | 832.16 Mn |
| Jun 30, 2025 | 816.44 Mn |
| Mar 31, 2025 | 866.55 Mn |
| Dec 31, 2024 | 903.33 Mn |
| Sep 30, 2024 | 933.22 Mn |
| Jun 30, 2024 | 947.03 Mn |
| Mar 31, 2024 | 457.23 Mn |
| Dec 31, 2023 | 482.02 Mn |
| Sep 30, 2023 | 216.37 Mn |
| Jun 30, 2023 | 229.43 Mn |
| Mar 31, 2023 | 247.35 Mn |
| Dec 31, 2022 | 97.85 Mn |